FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Fluvoxamine ER Capsules
Status: Currently in Shortage
»Date first posted: 02/05/2019
»Therapeutic Categories: Psychiatry

Expand all

Par Pharmaceutical (Revised 09/11/2019)

Company Contact Information:
800-828-9393, option 5 then option 2

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg. 30’s count (NDC 10370-175-11) Limited Inventory to be released during December 2019 Additional material will be further released for both 100 mg and 150 mg in February 2020. Shortage of an active ingredient
150 mg. 30’s count (NDC 10370-176-11) Limited Inventory to be released during November, December 2019 and January 2020 Additional material will be further released for both 100 mg and 150 mg in February 2020. Shortage of an active ingredient

Teva Pharmaceuticals (Reverified 09/17/2019)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03) Available Other
Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03) Available Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English